Clinical outcomes after 24 months of insulin therapy in patients with type 2 diabetes in five countries: results from the TREAT study

References

• Jönsson B; CODE-2 Advisory Board. Revealing the cost of type II diabetes in Europe. Diabetologia 2002;45:S5-12
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation. Global guideline for Type 2 diabetes. Brussels: International Diabetes Federation, 2005. Available at: http://www.idf.org/webdata/docs/IDF%20GGT2D.pdf [Last accessed July 2012]
   Google Scholar
• National Institute for Health and Clinical Excellence. Type 2 diabetes: national clinical guideline for management in primary care (update). London, UK: Royal College of Physicians/The National Collaborating Centre for Chronic Conditions, 2008. Available at: http://www.nice.org.uk/nicemedia/live/11983/40803/40803.pdf [Last accessed July 2012]
   Google Scholar
• Giugliano D, Maiorino MI, Bellastella G, et al. Multiple HbA1c targets and insulin analogues in type 2 diabetes: a systematic review. J Diabetes Complications 2011;25:275-81
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-79
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes – 2012. Diabetes Care 2012;35(Suppl 1):S11-63
   PubMed Web of Science ®Google Scholar
• Steinberg BA, Bhatt DL, Mehta S, et al. Nine-year trends in achievement of risk factor goals in the US and European outpatients with cardiovascular disease. Am Heart J 2008;156:719-27
   PubMed Web of Science ®Google Scholar
• Bloomgarden ZT. Achieving glycemic goals in type 2 diabetes. Diabetes Care 2007;30:174-80
   PubMed Web of Science ®Google Scholar
• Liebl A, Jones S, Benroubi M, et al. Clinical outcomes after insulin initiation in patients with type 2 diabetes: 6-month data from the INSTIGATE observational study in five European countries. Curr Med Res Opin 2011;27:887-95
   PubMed Web of Science ®Google Scholar
• Liebl A, Jones S, Goday A, et al. Clinical outcomes after insulin initiation in patients with type 2 diabetes: 24-month results from INSTIGATE. Diabetes Ther 2012;3:9
   PubMedGoogle Scholar
• Charuruks N, Milintagas A, Watanaboonyoungcharoen P, et al. Determination of reference intervals of HbA1C (DCCT/NGSP) and HbA1C (IFCC) in adults. J Med Assoc Thai 2005;88:810-16
   PubMedGoogle Scholar
• Landin-Olsson M, Jeppsson JO, Nordin G. [HbA1c – new standardization introduced in Sweden. The new unit is mmol/mol] [Article in Swedish]. Lakartidningen 2010;107:3282-5
   PubMedGoogle Scholar
• Trexler JC, Travis J. Nontraditional regression analyses. Ecology 1993;74:1629-37
   Web of Science ®Google Scholar
• Chow CC, Tsang LW, Sorensen JP, et al. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients. Diabetes Care 1995;18:307-14
   PubMed Web of Science ®Google Scholar
• Jones S, Benroubi M, Castell C, et al. Characteristics of patients with type 2 diabetes mellitus initiating insulin therapy: baseline data from the INSTIGATE study. Curr Med Res Opin 2009;25:691-700
   PubMed Web of Science ®Google Scholar
• Meneghini LF, Dornhorst A, Sreenan S; PREDICTIVE Study Group. Once-daily insulin detemir in a cohort of insulin-naïve patients with type 2 diabetes: a sub-analysis from the PREDICTIVE study. Curr Med Res Opin 2009;25:1029-35
   PubMed Web of Science ®Google Scholar
• Nichols GA, Koo YH, Shah SN. Delay of insulin addition to oral combination therapy despite inadequate glycemic control: delay of insulin therapy. J Gen Intern Med 2007;22:453-8
   PubMed Web of Science ®Google Scholar
• Rubino A, McQuay LJ, Gough SC, et al. Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with type 2 diabetes: a population-based analysis in the UK. Diabet Med 2007;24:1412-18
   PubMed Web of Science ®Google Scholar
• Shah S, Das AK, Kumar A, et al. Baseline characteristics of the Indian cohort from the IMPROVE study: a multinational, observational study of biphasic insulin aspart 30 treatment for type 2 diabetes. Adv Ther 2009;26:325-35
   PubMed Web of Science ®Google Scholar
• Blak BT, Smith HT, Hards M, et al. Optimization of insulin therapy in patients with Type 2 diabetes mellitus: beyond basal insulin. Diabet Med 2012;29:e13-20
   PubMed Web of Science ®Google Scholar
• Hsu WC. Consequences of delaying progression to optimal therapy in patients with type 2 diabetes not achieving glycemic goals. South Med J 2009;102:67-76
   PubMed Web of Science ®Google Scholar
• Eliasson B, Eeg-Olofsson K, Cederholm J, et al; Steering Committee of the Swedish National Diabetes Register (NDR). Antihyperglycaemic treatment of type 2 diabetes: results from a national diabetes register. Diabetes Metab 2007;33:269-76
   PubMed Web of Science ®Google Scholar
• Holman RR, Farmer AJ, Davies MJ, et al; 4-T Study Group. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009;361:1736-47
   PubMed Web of Science ®Google Scholar
• Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716-30
   PubMed Web of Science ®Google Scholar
• Jones S, Castell C, Goday A, et al. Increase in direct diabetes-related costs and resource use in the 6 months following initiation of insulin in patients with type 2 diabetes in five European countries: data from the INSTIGATE study. Clinicoecon Outcomes Res 2012;4:383-93
   PubMedGoogle Scholar
• Murata GH, Shah JH, Hoffman RM, et al. Intensified blood glucose monitoring improves glycemic control in stable, insulin-treated veterans with type 2 diabetes: the Diabetes Outcomes in Veterans Study (DOVES). Diabetes Care 2003;26:1759-63
   PubMed Web of Science ®Google Scholar
• Jain SM, Mao X, Escalante-Pulido M, et al. Prandial-basal insulin regimens plus oral antihyperglycaemic agents to improve mealtime glycaemia: initiate and progressively advance insulin therapy in type 2 diabetes. Diabetes Obes Metab 2010;12:967-75
   PubMed Web of Science ®Google Scholar
• Nichols GA, Kimes TM, Harp JB, et al. Glycemic response and attainment of A1C goals following newly initiated insulin therapy for type 2 diabetes. Diabetes Care 2012;35:495-7
   PubMed Web of Science ®Google Scholar
• Esposito K, Cozzolino D, Bellastella G, et al. Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Obes Metab 2011;13:594-603
   PubMed Web of Science ®Google Scholar
• Gale EA. Post-marketing studies of new insulins: sales or science? BMJ 2012;344:e3974
   PubMedGoogle Scholar